Ronald Krasnow Net Worth

The estimated Net Worth of Ronald A. Krasnow is at least $32.5 Thousand dollars as of 11 December 2019. Mr. Krasnow owns over 24,090 units of Menlo Therapeutics stock worth over $32,522 and over the last 5 years he sold MNLO stock worth over $0. In addition, he makes $0 as Chief Compliance Officer at Menlo Therapeutics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Krasnow MNLO stock SEC Form 4 insiders trading

Ronald has made over 1 trades of the Menlo Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 24,090 units of MNLO stock worth $32,522 on 11 December 2019.

The largest trade he's ever made was exercising 24,090 units of Menlo Therapeutics stock on 11 December 2019 worth over $32,522. On average, Ronald trades about 8,030 units every 0 days since 2019. As of 11 December 2019 he still owns at least 24,090 units of Menlo Therapeutics stock.

You can see the complete history of Mr. Krasnow stock trades at the bottom of the page.

Ronald Krasnow biography

Ronald A. Krasnow J.D. serves as Chief Compliance Officer of the Company. Prior to that, Mr. Krasnow served as General Counsel, Chief Strategy Officer and Secretary at Kinestral Technologies, Inc., a company focused on bringing cutting edge technology to the home and commercial construction markets, from December 2017 to December 2019. Prior to Kinestral, Mr. Krasnow spent approximately ten years as General Counsel at Relypsa, Inc. from 2007 to 2017, overseeing legal activities as the biotech company grew from a start-up, through its IPO, commercialization of its drug and its acquisition by Galenica. Prior to joining Relypsa, Mr. Krasnow spent ten years at Symyx Technologies, Inc. from 1997 to 2007 in various positions, including Senior Vice President, Intellectual Property. Earlier in his career, Mr. Krasnow was an attorney at Fish & Neave (now Ropes & Gray LLP) representing clients in complex patent litigation and interferences. Mr. Krasnow received his J.D. from The George Washington University Law School and his B.S. in Materials and Metallurgical Engineering from The University of Michigan.

How old is Ronald Krasnow?

Ronald Krasnow is 57, he's been the Chief Compliance Officer of Menlo Therapeutics since 2020. There are 5 older and 4 younger executives at Menlo Therapeutics. The oldest executive at Menlo Therapeutics, Inc. is Rex Bright, 79, who is the Director.

What's Ronald Krasnow's mailing address?

Ronald's mailing address filed with the SEC is 200 CARDINAL WAY, 2ND FLOOR, , REDWOOD CITY, CA, 94063.

Insiders trading at Menlo Therapeutics

Over the last 7 years, insiders at Menlo Therapeutics have traded over $3,825,000 worth of Menlo Therapeutics stock and bought 3,655,938 units worth $21,205,011 . The most active insiders traders include Advisors Llcperceptive Life..., Llc Fmr, and Albert Cha. On average, Menlo Therapeutics executives and independent directors trade stock every 85 days with the average trade being worth of $572,944. The most recent stock trade was executed by Sharon Barbari on 20 August 2020, trading 75,000 units of MNLO stock currently worth $111,000.

What does Menlo Therapeutics do?

Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded by Ed F. Schnipper in October, 2011 and is headquartered in Redwood City, CA.

Complete history of Mr. Krasnow stock trades at Menlo Therapeutics

Menlo Therapeutics executives and stock owners

Menlo Therapeutics executives and other stock owners filed with the SEC include:

• Elisabeth Sandoval,
  Independent Director
• Patrick LePore,
  Independent Director
• Anthony Bruno,
  Director
• Rex Bright,
  Director
• Sharon Barbari,
  Director
• Matthew Wiley,
  Chief Commercial Officer
• Mutya Harsch,
  Chief Legal Officer, General Counsel
• Ronald Krasnow,
  Chief Compliance Officer
• Iain Stuart,
  Chief Scientific Officer
• Andrew Saik,
  Chief Financial Officer, Treasurer
• David Domzalski,
  Chief Executive Officer, Director
• Steven L Basta,
  Director
• Advisors Llcperceptive Life...,
  
• Ilan Hadar,
  CFO and Country Manager
• Stanley Hirsch,
  Director
• Partners 2007 Gp, L.P.Presi...,
  
• Global Strategic Fund Ii L....,
  10% owner
• Ventures Llc Remeditex,
  10% owner
• Capital Viii, Llc Vivo Capi...,
  
• Albert Cha,
  Director
• Llc Fmr,
  
• Scott M Whitcup,
  Director
• Mary Spellman,
  Chief Medical Officer
• Kristine M Ball,
  See Remarks
• David W J Mcgirr,
  Director
• Paul L Berns,
  Director
• Ted Ebel,
  Director
• Aaron Royston,
  Director
• Paul Kwon,
  Chief Scientific Officer